396 related articles for article (PubMed ID: 23353839)
1. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
2. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
3. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
6. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
Cerna T; Hrabeta J; Eckschlager T; Frei E; Schmeiser HH; Arlt VM; Stiborová M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29304031
[TBL] [Abstract][Full Text] [Related]
7. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
8. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells.
Wang D; Zhu Q; Zhang X; Zhang L; He Q; Yang B
Pharmazie; 2010 Jan; 65(1):51-6. PubMed ID: 20187579
[TBL] [Abstract][Full Text] [Related]
10. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
Cinatl J; Kotchetkov R; Blaheta R; Driever PH; Vogel JU; Cinatl J
Int J Oncol; 2002 Jan; 20(1):97-106. PubMed ID: 11743648
[TBL] [Abstract][Full Text] [Related]
11. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M
Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid overcomes hypoxia-induced resistance to apoptosis.
Cipro Š; Hřebačková J; Hraběta J; Poljaková J; Eckschlager T
Oncol Rep; 2012 Apr; 27(4):1219-26. PubMed ID: 22159638
[TBL] [Abstract][Full Text] [Related]
16. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo.
Michaelis M; Suhan T; Cinatl J; Driever PH; Cinatl J
Int J Oncol; 2004 Dec; 25(6):1795-9. PubMed ID: 15547719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
